The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 17, 2025

Filed:

Apr. 27, 2022
Applicant:

New Jersey Institute of Technology, Newark, NJ (US);

Inventors:

Venkatesan Perumal, Newark, NJ (US);

Arun Reddy Ravula, Newark, NJ (US);

Namas Chandra, Newark, NJ (US);

Venkata Kakulavarapu RamaRao, Newark, NJ (US);

Vivek Kumar, Newark, NJ (US);

Zain Siddiqui, Paterson, NJ (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/65 (2006.01); A61K 9/16 (2006.01); A61K 47/60 (2017.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01); A61P 25/28 (2006.01); A61P 27/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/65 (2013.01); A61K 9/1658 (2013.01); A61K 47/60 (2017.08); A61K 47/644 (2017.08); A61K 47/6929 (2017.08); A61P 25/28 (2018.01); A61P 27/16 (2018.01);
Abstract

A composition, and method for a targeted drug delivery is disclosed in treating central nervous system injury, including blast hearing loss, traumatic brain injury (TBI) and the like, by administering a subject with nanoparticle-based minocycline formulations. The formulation contains nanoparticles encapsulating minocycline for neuroprotective effect in TBI. Albumin nanoparticle-based minocycline formulations provide enhanced delivery to brain, and reduced toxicity at minimal dosage for treating a subject suffering from central nervous system injury including blast induced traumatic brain injury (bTBI). Nanoparticle administered at minimal dose in rat blast TBI model crossed blood-brain barrier (BBB) and enhanced therapeutic concentration compared to free minocycline. Provided is an effective and safe minocycline delivery in TBI with minimal or no toxicity for neuroprotective therapy. Studies indicate performance for behavioral (acute and chronic), pathological (chronic) and hearing loss mitigation using the disclosed drug and nanoparticles in rat moderate bTBI model.


Find Patent Forward Citations

Loading…